In this sense, in some clinical trials, it has been reported that, with doses between 200 and 1000 mg/day of RV, the levels of glucose, insulin, HbA1c and insulin resistance are reduced [33,34,35,36] in subjects with T2D younger than 50 years. The gene discussed is INS; the disease is Insulin resistance.